Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Palmoplantar Pustulosis
Interventions: Bimekizumab, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more

Conditions: Psoriasis
Interventions: Guselkumab, Placebo for guselkumab, Etanercept; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Macon, Georgia + 7 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 50
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 45 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis
Interventions: Etanercept / Autoinjector A; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more

Conditions: Psoriatic Arthritis
Interventions: NDI-034858, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Palm Desert, California • Upland, California • Hollywood, Florida + 19 more

Conditions: Generalized Pustular Psoriasis
Interventions: 750 mg Imsidolimab, 300 mg Imsidolimab, Placebo; Drug · Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Psoriasis, Psoriasis Vulgaris, Skin Diseases
Interventions: Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone; Device · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 89 Years
Enrollment: 171 participants
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Psoriasis
Interventions: Desoximetasone 0.05% once daily, Desoximetasone 0.05% twice daily, Desoximetasone 0.25% once daily, Vehicle once daily, Vehicle twice daily; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Miami, Florida • Martinez, Georgia • Olathe, Kansas + 4 more

Conditions: Psoriasis
Interventions: Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more

Conditions: Plaque Psoriasis
Interventions: Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 125 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 33
States / cities: Mobile, Alabama • Bakersfield, California • Beverly Hills, California + 26 more

Conditions: Psoriasis
Interventions: Clobetasol Propionate, 0.05%, Clobetasol propionate, 0.05% Spray; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Cedar Knolls, New Jersey

Conditions: Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: Not listed
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2050
U.S. locations: 54
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more

Conditions: Psoriatic Arthritis
Interventions: CNTO 1275 63 mg, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 12
States / cities: Macon, Georgia • Boise, Idaho • Normal, Illinois + 9 more

Conditions: Plaque Psoriasis, Psoriasis
Interventions: Enstilar® foam, Vehicle foam; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Moderate to Severe Nail Psoriasis
Interventions: Secukinumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more

Conditions: Plaque Psoriasis
Interventions: Halobetasol Topical Lotion; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Fountain Valley, California • Hialeah, Florida • Saint Joseph, Missouri

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 20 more

Conditions: Psoriasis
Interventions: DPS-102, Vehicle / Placebo, Calcipotriol Monotherapy, Nicotinamide Monotherapy; Drug · Other
Lead sponsor: DermiPsor, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Brockton, Massachusetts

Conditions: Psoriasis
Interventions: ustekinumab, placebo; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more

Conditions: Psoriatic Arthritis
Interventions: 210 mg brodalumab, 140 mg brodalumab, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 40 more

Conditions: Psoriasis
Interventions: Risankizumab, Autoinjector; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

Iontophoresis in Psoriasis

Psoriatic Arthritis Research Collaborative: Biologic Sub-Study

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

Low Dose Naltrexone for Chronic Pain From Arthritis

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis